@article {Mason220, author = {Ursula Mason and Jose Aldrich and Ferdinand Breedveld and Charles B Davis and Michael Elliott and Mildred Jackson and Christian Jorgensen and Edward Keystone and Robert Levy and John Tesser and Mark Totoritis and Alemseged Truneh and Michael Weisman and Craig Wiesenhutter and David Yocum and Jin Zhu}, title = {CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.}, volume = {29}, number = {2}, pages = {220--229}, year = {2002}, publisher = {The Journal of Rheumatology}, abstract = {OBJECTIVE: Double blind studies were conducted with the anti-CD4 monoclonal antibody (Mab) keliximab in patients with active, stable rheumatoid arthritis (RA), to confirm preliminary evidence of efficacy and safety from open. uncontrolled studies. METHODS: We enrolled 136 and 186 patients into 2 consecutive, randomized, double blind trials, with similar populations [apart from inclusion of disease modifying antirheumatic drug (DMARD)-na{\"\i}ve patients in Study 2]. Patients received 4 weeks intravenous placebo or keliximab [40, 80, 120, or 140 mg twice weekly (bw), or 240 mg once weekly (ow)].The primary endpoint was the American College of Rheumatology (ACR) 20 response criteria, one week after the end of treatment. RESULTS: ACR 20 response rates in Study I were 19\%, 42\%, 51\%*, and 69\%* (*p \< 0.05 compared to placebo), with placebo, 40, 80, or 140 mg keliximab bw, respectively. The response rates in Study 2 were 30\%, 39\%, 46\% and 47\% with placebo, 80 or 120 mg bw, or 240 mg keliximab ow, respectively. In the 2 studies, there was a dose dependent increase in peripheral blood CD4+ T cell coating with keliximab, but a different pattern of CD4 depletion was seen. While only 12\% of keliximab treated patients in Study I had CD4 counts below 250 cells/mm3 at the end of the treatment period, 47\% fell below this level in Study 2. Clinical response was not correlated with CD4 depletion, but was correlated with CD4+ T cell coating with keliximab. CONCLUSION: Coating of peripheral blood CD4+ T cells with keliximab, but not CD4 depletion, is a determinant of clinical response.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/29/2/220}, eprint = {https://www.jrheum.org/content/29/2/220.full.pdf}, journal = {The Journal of Rheumatology} }